The ongoing mission of the Michigan Cancer Research Consortium (MCRC) NCORP is to improve the oncologic health of the communities it serves by assuring access to state-of-the- art clinical trials. MCRC will achieve this goal through participation in cancer control and prevention, screening, cancer care delivery, treatment and other relevant human subjects research to contributing to knowledge development in the field of oncology care. The MCRC will utilize its proven resources to serve the objectives of the National Cancer Institute's NCORP program. First funded in 1994 as a single hospital CCOP, the MCRC is now comprised of 15 hospitals and 85 oncology investigators from 47 practices in three states. By strategically leveraging our partnerships with the NCI Comprehensive Cancer Centers and other funding sources, MCRC will contribute to the development of the next generation of studies particularly in the area of Cancer Care Delivery Research with a focus on reducing cancer disparities.
Our specific aims are: Serve Our Patients - Meet our patients needs as one of the strongest performing NCORP programs within the NCI network, providing access to protocols. Advance Cancer Care Delivery Research (CCDR) ? Utilize our unique community infrastructure and support from our strategic partnerships and NCTN counterparts to conduct CCDR protocols that address major issues in the delivery of cancer care . Decrease Cancer Disparities - Assure our consortium of community sites stay at the forefront of understanding how disparities affect outcomes of the patients we serve while implementing and studying the impact of targeted interventions to reduce disparities. Expand Biorepository Banking - Expand our successful biorepository banking to all MCRC hospitals so we can provide high quality, fully-annotated tissues to researchers. Aligned with NCI goals, focus on innovative trials exploring the biologic basis of cancer treatment and symptom science - Explore the interface between genomics, immune system and host milieu through innovative trials.

Public Health Relevance

The overall goal of NCORP is to bring cancer clinical research studies to individuals in their own communities, thereby generating a broadly applicable evidence base that contributes to improved patient outcomes and a reduction in cancer disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189971-06
Application #
9768629
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Lee, Cecilia H
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-19
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Saint Joseph Mercy Health System
Department
Type
DUNS #
807606249
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465

Showing the most recent 10 out of 19 publications